Esophageal Cancer Molecular Diagnostics Market Size

  • Report ID: 6129
  • Published Date: Jun 07, 2024
  • Report Format: PDF, PPT

Esophageal Cancer Molecular Diagnostics Market Size

Esophageal Cancer Molecular Diagnostics Market size was valued at USD 4.18 Billion in 2023 and is poised to reach USD 11.54 Billion by the end of 2036, registering around 7.65% CAGR during the forecast period i.e., between 2024-2036.

The esophageal cancer market is slated to dilate in the upcoming years owing to increased prevalence due to obesity and bad lifestyles, which in turn would snowball into a high dependency on various oesophageal cancer diagnostic equipment. 

Additionally, the government and non-government organizations are pushing campaigns in developing countries for people at risk to understand their symptoms, take adequate steps to get diagnosed, and access a tailored treatment plan. With diagnostic tests like bronchoscopy, molecular testing, PET, etc offering a straightforward diagnosis, and predicting the prognosis, the market for esophageal cancer molecular diagnostics is burgeoning even in developing countries now, as the patients are conscious of their options.


Esophageal Cancer Molecular Diagnostics Market Overview
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 6129
  • Published Date: Jun 07, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of esophageal cancer molecular diagnostics was over USD 4 billion.

The market size for esophageal cancer diagnostics is forecasted to cross USD 11.54 billion by the end of 2036 expanding at a CAGR of 7.65% in the predicted timeline mentioned i.e., between 2024-2036.

The major players in the market are Roche Diagnostics, Chordia Therapeutics, Otsuka Pharmaceutical Co., Ltd, Agilent Technologies, Inc., Thermo Fisher Scientific, Illumina Inc., and others.

The genetic tests segment is anticipated to achieve a share/size of 55% during 2024-2036.

The Asia Pacific esophageal cancer molecular diagnostics sector is poised to hold a 60% share by the end of 2036.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample